US › Healthcare

Genprex Inc (GNPX)

US · Healthcare · Biotechnology

$4.42-6.95%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Revenue YoY

-100.0%

Net profit

$-4.5M

Profit YoY

-12.5%

EPS

$-14.12

Key statistics

Market cap

$3.0M

Forward P/E

0.0

P/B

0.18

Book value

$41.18

EPS (TTM)

$-111.32

52-week high

$1,210.00

52-week low

$4.65

50-day MA

$12.08

200-day MA

$56.35

Beta

-0.91

Analyst view

Analysts rate Genprex Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $7.50.

Shareholding

Insiders

0.35%

Institutions

0.71%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.30%
Mayflower Financial Advisors, LLC	0.18%
Vanguard Capital Management, LLC	0.05%
Cygnus Capital Advisors, LLC	0.02%
JONES FINANCIAL COMPANIES LLLP	0.02%
Citigroup Inc	0.02%
Cheviot Value Management, Inc.	0.01%
Advisor Group Holdings, Inc.	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Genprex Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.